Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Korea Institute of Science and Technology

Catholic University Industry Academic Cooperation Foundation

Young Gil Ahn

Tae Woo Kim

In Hwan Bae

Kwee Hyun Suh

Jae Yul Choi

Seung Hyun Jung

Ji Sook Kim

Maeng Sup Kim

Ji Young Song

Young Jin Ham

Seok Jong Kang

Jung Beom Son

Seo Hee Kim

Eun Young Byun

Jae Chul Lee

Chang Hee Park

Eun Joo Kwak

Won Jeoung Kim

Young Hee Jung

Keuk Chan Bang

Ho Seok Kim

Seung Ah Jun

Sang Mi Han

Hwan Mook Kim

Hwan Geun Choi

Tae Bo Sim

Bum Woo Park

Jong Won Choi

Ji Young Hwang

Dong-sik Park

Dong Jin Hong

Yong Hoon An

Dong-wook Kim

Gwan Sun Lee

Eun Young Kim

Ji Yeon Song

Jung Mi Hah

Hwan Oh Kim

Mi Young Cha

Dong-Sik Park

Moon Sub Lee

Mi Kyoung Lee

Nam Du Kim

Tae Hun Song

Mi Yon Shim

Wha Il Choi

Shin Mee Mah

Eun Ju Jeon

In Ho Yang

Myoung Sil Ko

Kyu Hang Lee

So Min Park

Hae Kyoung Ju

Wha Ii Choi

Jung Soo Nam

Min Jeong Kim

Dong-Wook Kim

Hwan Kim

Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Imidazopyridine derivative compounds and use of same

Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.

Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

A novel heterotricyclic compounds of Formula 1 or pharmaceutically acceptable salts thereof, and uses thereof are disclosed. The novel heterotricyclic compounds exhibit an inhibitory activity against EZH1 (enhancer of zeste homolog 1) and/or EZH2 (enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing these compounds as active ingredient is also disclosed. The heterotricyclic compound, pharmaceutically acceptable salts thereof, or compositions containing the compound or salt are useful in treating tumor or cancer in a subject.

Heterotricyclic derivative compound and use of same

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

The present invention relates to a crystalline form of a salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and a pharmaceutical composition containing the same. The crystalline form of the salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.

Salts of 4-amino-N-(l-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-D]pyrimidine-7-carboxamide, and crystalline forms thereof

Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.

Dioxoloisoquinolinone derivatives and use thereof

The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.

Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase

Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Pyrazole derivative compound and use thereof

A novel imidazopyridine derivative compound and uses thereof are disclosed. An imidazopyridopyridine derivative compound of Chemical Formula 1 having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the compound are disclosed: 

Imidazopyridopyrimidine derivative compound and use thereof

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Pyrimidine compound and pharmaceutical use thereof

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases

Growing community of inventors

Seongnam-si, South Korea

Young Gil Ahn